Celina Ang, MD
- ASSISTANT PROFESSOR | Medicine, Hematology and Medical Oncology
- Cancer (Oncology)
- Hospital Affiliation
- The Mount Sinai Hospital
- Ruttenberg Treatment Center 212-241-6756212-241-6756
American Board of Internal Medicine
- Gastrointestinal Cancers
- Liver Cancer
MD, University of Western Ontario
BSc, McGill University
Residency, Internal Medicine
Montreal General Hospital
Fellowship, Gastrointestinal Oncology
Memorial Sloan-Kettering Cancer Center
Clinical training and research grant
Fibrolamellar Cancer Foundation
Montreal General Hospital Foundation Research Award
Dr. L. DeWitt Wilcox Award in Medical Research
Schulich School of Medicine & Dentistry, The University of Western Ontario
James McGill Entrance Scholarship
Ang C, Chambers AF, Tuck AB, Winquist E, Izawa JI. Plasma osteopontin levels are predictive of disease stage in patients with transitional cell carcinoma of the bladder. BJU international 2005 Nov; 51(6).
Ang C, Guiot MC, Ramanakumar AV, Roberge D, Kavan P. Clinical significance of molecular biomarkers in glioblastoma.. Can J Neurol Sci 2005 Oct; 37(5): 625-30.
Ang C, Hauerstock D, Guiot MC, Kasymjanova G, Roberge D, Kavan P, Muanza T. Characteristics and outcomes of medulloblastoma in adults. Pediatric blood & cancer 2008 Feb; 51(5).
Ang C, Kornbluth M, Thirlwell M, Rajan R. Capecitabine-induced cardiotoxicity: case report and review of the literature. Current oncology (Toronto, Ont.) 2010 Sep; 17(1).
Cohen V, Agulnik J, Ang C, Kasymjanova G, Batist G, Small D, Brandao G, Chong G, Miller WH. Epidermal growth factor receptor mutations detected by denaturing high-performance liquid chromatography in nonsmall cell lung cancer: impact on response to therapy with epidermal growth factor receptor-tyrosine kinase inhibitors. Can J Neurol Sci 2010 Sep; 37(18).
Ang C, O'Reilly EM, Abou-Alfa GK, Shamseddine A, Skouri H, Tawil A, Eloubeidi MA, Lowery M, Kharfan-Dabaja M, Kaprealian T, Temraz S, Sibai H, Farran H, Shah MA. Gastrointestinal cancer educational case series: management of metastatatic adenocarcinoma of unknown primary origin in a Ph+ ALL survivor.. J Gastrointest Cancer 2011 Sep; 42(3): 165-70.
Postow M, Shah MA, Lowery M, Shamseddine A, El-Kutoubi A, Al Olayan A, Naghy M, Ang C, Tamraz S, Jazieh AR, O'Reilly EM, Kelsen DP, Abou-Alfa GK. A man with Klinefelter's syndrome and new abdominal distension: a discussion of evaluation and management. Journal of gastrointestinal cancer 2012 Jun; 43(2).
Ang C, O'Reilly EM, Abou-Alfa GK. MicroRNA, hypoxic stress and hepatocellular carcinoma: future directions [editorial]. J Gastroenterol Hepatol 2011 Nov; 26(11): 1686-8.
Ang C, Janjigian YY, Shamseddine A, Tawil A, Lowery MA, Intlekofer A, Faraj W, Al-Olayan A, Tang L, O'Reilly EM, Geara F, Al-Kutoubi A, Kelsen DP, Abou-Alfa GK. A case of advanced gastric cancer. Gastrointestinal cancer research : GCR 2012 Mar; 5(2).
Ang C, O'Reilly EM, Abou-Alfa GK. Targeted agents and systemic therapy in hepatocellular carcinoma. Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 2013; 190.
Abou-Alfa GK, Ang C. Dx/Rx Liver Cancer 1st Edition. Burlington, MA, Jones & Bartlett Learning;.
Ang C, Abu-Alfa AK, Abdullah K, Lowery M, Sibai H, El Farran H, Tamraz S, Al Olayan A, Shamseddine A, Naghy M, Faraj W, O'Reilly EM, Abou-Alfa GK. Hepatocellular carcinoma following renal transplantation. Gastrointestinal cancer research : GCR 2011 Sep; 4(5-6).
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Ang did not report having any of the following types of financial relationships with industry during 2017 and/or 2018: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.